Innate Pharma: First Patient Dosed in Phase 3 Lung Cancer Trial Triggers $50M AstraZeneca Pay

 

• First patient dosed in Phase 3 trial, PACIFIC-9, evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable, Stage III non-small cell lung cancer

• Milestone payment further bolsters Innate’s cash position

• Second Phase 3 monalizumab trial now initiated by AstraZeneca

https://finance.yahoo.com/news/innate-pharma-first-patient-dosed-050000252.html